Acceleron Pharma's products include novel bone forming agents to treat cancer-related bone loss, muscle mass agents to treat diseases involving muscle loss, and protein therapeutics to bind a member of the growth and differentiation factor family necessary for angiogenesis. The company develops therapies based on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival of various tissue types. Acceleron generates revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates.